International requirements for the conduct of clinical trials continue to evolve in response to advances in scientific methodology, digital technologies, and drug development practices. The revised ICH GCP E6(R3) guideline reflects this shift, placing greater emphasis not only on compliance with established procedures but also on systematic quality management, risk assessment, and the protection of clinical trial participants.

For sponsors, contract research organizations (CROs), and clinical trial sites, the revised guideline calls for a reassessment of existing approaches to clinical trial planning, conduct, oversight, and quality control.

What Is ICH GCP E6(R3)?
ICH GCP E6(R3) is the revised version of the International Council for Harmonisation (ICH) guideline on Good Clinical Practice (GCP). It establishes principles for the ethical and scientifically sound conduct of clinical trials involving human participants.
Its primary objectives are to protect the rights, safety, and well-being of trial participants and to ensure the reliability and integrity of clinical trial data.
The revision reflects changes in the clinical research landscape, including the increased use of electronic systems, evolving collaboration models among stakeholders, and the development of decentralized clinical trial approaches.
One of the central themes of E6(R3) is quality management throughout the clinical trial lifecycle. This means that quality considerations should be incorporated into protocol development and trial planning from the outset, rather than addressed solely through subsequent monitoring and oversight activities.

Quality Begins at the Design Stage
A key principle of the revised guideline is Quality by Design (QbD), which emphasizes building quality into clinical trial design and operational processes from the beginning.
In practice, this requires the early identification of critical-to-quality factors: those processes and data essential to protecting trial participants and ensuring the reliability of trial results. This assessment provides the basis for designing appropriate quality controls, allocating resources, and implementing measures to prevent or mitigate potential issues.
During trial planning, organizations should consider:

• Which factors could affect participant safety and well-being.
• Which data are critical to the trial objectives and the reliability of its results.
• Where errors, protocol deviations, or process failures are most likely to occur.
• Which risk control measures are necessary and proportionate to the identified risks.
• How the effectiveness of these measures will be evaluated.

This approach enables sponsors and CROs to focus resources on the aspects of trial conduct that matter most for participant protection and data reliability, while avoiding unnecessary controls over processes that have limited impact on overall trial quality.

Risk Management Throughout the Clinical Trial Lifecycle
ICH GCP E6(R3) reinforces a risk-based approach to quality management. Risk assessment should reflect the specific characteristics of each clinical trial and consider the potential impact of identified risks on participant safety, trial conduct, and data reliability.
For sponsors and CROs, this requires a structured process for risk identification, assessment, control, communication, and ongoing review.
Depending on the trial design and operational context, this process may include:

• Conducting risk assessments before trial initiation.
• Identifying critical processes and critical-to-quality data.
• Developing preventive measures and mitigation strategies.
• Documenting, assessing, and trending protocol deviations and other quality events.
• Investigating recurring issues and determining their root causes.
• Implementing corrective and preventive actions (CAPA) and evaluating their effectiveness.

When a deviation or quality issue occurs, documentation alone is not sufficient. Organizations should assess its impact, investigate the underlying cause, and determine what actions are needed to prevent recurrence.
A robust quality management system should therefore support continuous improvement throughout the trial lifecycle, rather than relying exclusively on retrospective detection of non-compliance.

Sponsor and CRO Responsibilities: A Coordinated Oversight Framework
Clinical trial quality depends on effective collaboration among all parties involved. However, the delegation or outsourcing of trial-related activities does not eliminate the need for clearly defined responsibilities and appropriate oversight.
The sponsor is responsible for establishing and maintaining an appropriate system of oversight for the clinical trial. The CRO is responsible for performing the activities entrusted to it in accordance with applicable requirements, the clinical trial protocol, contractual arrangements, and relevant procedures.
Particular attention should be paid to:

• Clearly defining and documenting roles, responsibilities, and delegated activities.
• Ensuring personnel are appropriately qualified, trained, and competent.
• Maintaining oversight of delegated trial activities.
• Coordinating activities across clinical trial sites, CRO teams, and other service providers.
• Identifying deviations and quality issues promptly and ensuring appropriate follow-up.
• Maintaining complete, accurate, and traceable trial documentation.

An effective quality management system requires more than documented procedures. All stakeholders must understand their responsibilities, and the processes established to support trial quality must operate effectively in practice.

Electronic Data and Digital Systems
The growing use of digital technologies creates new opportunities for clinical trial management while increasing the importance of robust data governance.
Electronic systems must support reliable data handling, controlled access, traceability of changes, and protection against data loss or unauthorized modification.
Depending on the systems used and the nature of the trial, organizations should pay particular attention to:

• The suitability and validation of computerized systems, where applicable.
• Role-based access controls and appropriate user permissions.
• Audit trails and the traceability of data changes.
• Data backup, recovery, and business continuity arrangements.
• Data integrity, accuracy, completeness, and traceability throughout the data lifecycle.
• The protection of confidential information and personal data.

The objective is not simply to adopt electronic tools but to demonstrate that the systems are fit for their intended purpose and support the reliability, security, and integrity of clinical trial data throughout the study.

Participant Protection Remains the Priority
Strengthening quality management processes does not change the fundamental principle of GCP: the rights, safety, and well-being of clinical trial participants take precedence.
In operational terms, this requires particular attention to the informed consent process, protocol compliance, the recording and assessment of adverse events, personal data protection, and timely escalation of safety concerns to the appropriate parties.
Where a trial incorporates remote assessments, decentralized procedures, or digital communication channels, organizations should also evaluate how these arrangements affect participant safety, the quality of collected data, and compliance with the protocol and applicable requirements.
The implementation of new technologies and operating models must remain consistent with the fundamental principles of ethical and scientifically sound clinical research.

What Should Clinical Research Organizations Review?
Preparing for the implementation of revised GCP requirements should begin with an assessment of the existing quality management system and the identification of processes that may require improvement.

Depending on the organization's role and the nature of its clinical trials, the following activities may be appropriate:

1. Review existing standard operating procedures (SOPs) to assess alignment with applicable GCP requirements.
2. Reassess risk management processes, including risk identification, evaluation, mitigation, and ongoing review.
3. Verify the allocation of responsibilities among the sponsor, CRO, clinical trial sites, and other service providers.
4. Evaluate electronic data management procedures and the suitability of computerized systems.
5. Update training programs and processes for documenting personnel qualifications and competency.
6. Review deviation management and CAPA processes, including root cause analysis and the assessment of corrective and preventive action effectiveness.
7. Verify implementation in practice, ensuring that revised procedures are reflected in operational workflows and supported by appropriate documentation.

Updating SOPs alone does not guarantee compliance. Organizations must also assess whether procedures are consistently followed in practice and whether they effectively achieve their intended quality objectives.

ICH GCP E6(R3): Moving from Procedural Compliance to Quality Management
The revised guideline strengthens the role of a systematic, risk-based approach to clinical trial quality. Effective quality management is not determined by the number of procedures or documents an organization maintains, but by its ability to anticipate and mitigate risks, maintain oversight of critical processes, and ensure the reliability of clinical trial data.
For sponsors and CROs, E6(R3) provides an opportunity to reassess trial operations, improve transparency and coordination among stakeholders, and establish a more consistent and effective quality management framework.

Vita Aeterna provides contract research services across the clinical trial lifecycle, from study planning through to final reporting, supporting sponsors in the organization and conduct of clinical trials. Effective planning, clearly allocated responsibilities, and a sustained focus on quality at every stage provide the foundation for reliable results and the protection of trial participants.

Clinical trial quality is built throughout the entire study lifecycle — from protocol development and trial planning to study completion and final reporting.